P. Square Medical Ltd., an Israeli startup company, today announced that it has signed an agreement with the Premier Applied Sciences® division of Premier Inc., a leading healthcare improvement company, to collaborate on a trial project using the PeePalTM system, at the Thomas Jefferson University Hospital's Department of Urology, in Philadelphia. It was further stated that successful results are expected to lead to expanding the joint efforts with Premier to launch the system in the U.S. market.
The PeePal system is intended for the diagnoses and monitoring of male urinary disorders at home or in-clinic, in a simple and easy-to-use manner. The prevalence of benign prostate hyperplasia (BPH) and bladder outlet obstruction (BOO) are a major cost driver to the U.S. healthcare system. More than 50 percent of men over the age of 50 suffer from a certain level of BPH, and the majority of these men are monitored for the progression of the disease using diagnostic tools that may cause pain and require multiple in-person visits to the clinic or hospital each year.
"We are excited to begin working with Premier to evaluate PeePal in the U.S. market,” said Yosi Rozenberg, CEO and Co-Founder of P. Square Medical. “The PeePal system features an easy-to-use remote patient monitoring system that is perfectly aligned with digital health support. We are eager to begin this research process and look forward to hopefully introducing this revolutionary product to patients in communities across this country.”
P. Square Medical’s technology aims to harness technological advancements for the healthcare system to improve outcomes, lower costs, reduce disparities and ensure equitable distribution of cost burdens to secure financial solvency for providers. The COVID-19 pandemic has further amplified the need for less invasive, digital health systems, such as PeePal, that help keep patients out of the acute care setting.
“We are looking forward to working with the P. Square Medical team to answer important research questions and providing statistical analysis of the PeePal study results,” said Myla Maloney, Vice President of Strategy and Commercial Operations, Applied Sciences at Premier. “This is a testament to our research team’s ability to provide guidance in various phases of evaluation of new products in the U.S. We believe that this is yet another manifestation of Premier’s vision in servicing the U.S. healthcare system by collaborating with producers of advanced medical technologies such as PeePal.”
The insights you need to stay ahead in healthcare: Subscribe to Premier’s Power Rankings newsletter and get our experts’ original content delivered to your inbox once a month.